The classic view of neurotoxicity in neurodegenerative diseases is based upon the idea that a specific neuronal population is especially vulnerable to a cumulative toxic burden-for example, in dominantly inherited disease, burden from intraneuronal damage due to accumulation of a toxic mutant protein. Chronic damage combined with normal aging drives this deleterious action to a threshold that overwhelms the neuron's defensive mechanisms, triggering degeneration and neuronal death or both (reviewed in ref. 1 ). An initial view was that this mechanism would be cell autonomous: that is, independent of mutant damage accumulated within other cell types that interact with the affected neurons.
Evidence from genetic or chemical mimics in mice of diverse human neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Huntington's disease, Parkinson's disease and multiple system atrophy (MSA), have, however, shaken this classic view. There is now powerful evidence for non-cellautonomous mechanisms in which neurodegeneration is strongly influenced by toxicity or mutant protein expression in both neuronal and non-neuronal cells in the neighborhood of the vulnerable neurons, especially the CNS glial cells: astrocytes [2] [3] [4] [5] , oligodendrocytes 6 and microglia [7] [8] [9] , each of which have intimate contact with neurons ( Fig. 1) .
The main question for glial involvement and its contribution to noncell-autonomous mechanisms in diseases that have classically been thought of as primary 'neuro'-degenerative diseases is whether interaction within or between glial or neuronal cells, as opposed to toxicity arising solely within vulnerable neurons, is necessary for, or contributes to, the neurodegenerative process. Three different pathways of glial involvement in non-cell-autonomous degeneration of the vulnerable neurons can be imagined: (i) toxicity within the affected neurons could stimulate damaging responses from glia that are not directly damaged by this toxicity or by their own synthesis of the mutant protein; (ii) mutant protein expression (or toxicity) in glial cells could disturb a normal glial response, amplifying initial damage to the vulnerable neurons; or (iii) mutant protein expression (or toxicity) within glia could disturb normal glial function, thus becoming a primary source of neurotoxicity, potentially independent of mutant (or toxic) effects within the neurons at risk. The latter two possibilities blur the lines between diseases previously thought to be of primary neuronal origin (including ALS, SCA, Huntington's disease, Parkinson's disease and partly also MSA) and those that are of primary glial origin, accompanied by secondary neurodegeneration (including multiple sclerosis and certain forms of Charcot-Marie-Tooth disease, related to either myelinating oligodendrocytes or Schwann cells, respectively) (Fig. 1) . We focus here on examples, especially ALS and type 7 SCA (SCA7), where molecular genetic methods in mice have demonstrated a non-cell-autonomous disease mechanism in which damage within glia, especially astrocytes and microglia, is essential in toxicity.
Astrocytes: interlinked gatekeepers of glutamate Astrocytes provide essential services to the neurons they support, including roles in synapse formation, maintenance and plasticity, as well as regulation of cerebral blood flow (reviewed in ref. 10). They transport various nutrients and metabolic precursors to neurons (through the malate-aspartate shuttle) and are central to extracellular potassium homeostasis by means of their potassium channels located at synapses and at astrocytic 'end-foot' processes juxtaposed to capillaries. They are probably best known for their essential roles in the catabolism of several amino acids, especially rapid recovery of glutamate, the primary excitatory neurotransmitter in the CNS, from synaptic clefts by astrocytic glutamate transporters (GLT-1 and GLAST, also known as EAAT2 and EAAT1 respectively) and for returning glutamate (in the form of glutamine) to neurons (through the glutamate-glutamine shuttle).
Less appreciated is that astrocytes are not just single cells: they are networked together by a series of gap junctions that, among other things, propagate calcium waves throughout the linked astrocyte network 10 . This could become important when considering how they might contribute to spreading damage from an initiating focal point.
Microglia: resident macrophages of the CNS Microglia, the macrophages of the CNS, have well established roles in the programmed elimination of neural cells during development and in maintaining normal neuronal survival by removing toxic cellular debris (reviewed in ref. 11). Their main role in the adult CNS is linked to neuroinflammation in disease and injury. Their surveillance systems lie in wait for damage signals that stimulate their activation, migration to the site of damage, and proliferation. As key components of the inflammatory response, microglia-known to be a double-edged sword, with both neurotoxic and neurotrophic effects-are mobilized in essentially all examples of disease and injury to the CNS 11 .
Astrocytes and microglia as key contributors in ALS ALS is the most prominent adult motor neuron disease, characterized by progressive, fatal paralysis from degeneration and death of upper brain and lower spinal cord motor neurons (reviewed in ref. 12) . Although most instances occur as sporadic disease without an apparent genetic origin, approximately 10% (referred to as familial ALS) are caused by a dominant mutation. Sporadic and familial ALS produce similar pathologies, with selective loss of the same set of vulnerable motor neurons. About a quarter of the inherited cases are due to missense mutations in the ubiquitously expressed enzyme superoxide dismutase 1 (SOD1), whose enzymatic activity is to destroy the highly reactive oxygen radical superoxide 12 .
Mimics of familial ALS have been produced for half a dozen of the 4115 disease-associated SOD1 mutants. Expression of mutant SOD1, but not a comparable increase in synthesis of wild-type SOD1, generates age-dependent, progressive, fatal paralysis in mice and rats when the mutant is either ubiquitously expressed (from transgenes using the authentic Sod1 transcriptional promoter [12] [13] [14] or expressed broadly in neurons and glia (using transgenes carrying the promoter from the prion protein gene Prnp 15 ) (Fig. 2a) . A consensus has emerged that disease results from a gain of toxic property by the mutant protein, not from a loss of enzymatic activity 12, 13, 16 . Indeed, complete absence of SOD1 does not compromise life span in laboratory mice nor provoke motor neuron disease 12 .
Absence of degeneration or disease upon synthesis of mutant SOD1 solely within neurons, using either the Thy1 (ref. 17) or Nefl (neurofilament light chain) 18 promoters, provided the initial evidence that disease probably does not arise strictly from damage caused by the mutant within the vulnerable motor neurons (Fig. 2b) . Analysis of chimeric mice that were mixtures of normal cells and cells expressing high levels of mutant SOD1 provided even more direct evidence for a non-cell-autonomous disease mechanism. Motor neurons surrounded by higher numbers of normal neighbors survived longer without degeneration despite expressing high levels of mutant SOD1, whereas genetically normal motor neurons were damaged by their mutantexpressing neighbors 19 .
Disease onset was delayed and survival extended after partial removal from only motor neurons (using an Isl1 promoter-driven Cre transgene that is expressed within the spinal cord) of a ubiquitously expressed mutant Sod1 transgene 8 (Fig. 2a) . The rate of disease progression once onset occurred, however, was almost unaffected. Similarly, virusmediated small interfering RNA knock-down that within the CNS suppressed mutant SOD1 selectively within motor neurons greatly delayed onset 20, 21 , but disease progression was slightly accelerated 20 . Thus, mutant synthesis within motor neurons is a central contributor to disease initiation, but only a minor player in disease progression.
So what of the contribution to disease of mutant SOD1 expression within astrocytes and microglia? Both ALS mice and patients develop prominent features of neuroinflammation, including astrogliosis and microgliosis (reviewed in refs. 10,12,13); and minocycline, a tetracycline derivative with anti-inflammatory activity, extends survival in ALS mice 22 .
The clearest evidence is for damage by mutant protein developed within microglia as a contributor to disease progression (Fig. 2a) . Although partial excision of a ubiquitously expressed mutant Sod1 transgene from cells of the myeloid lineage, including microglia (using Figure 1 Insights from animal models of diverse human neurodegenerative diseases indicate that disease mechanisms are non-cell-autonomous, requiring the convergence of damage within the vulnerable neurons and their neighboring glial cells. Glia-derived toxicity can strongly influence disease progression (for example, in ALS 7, 8 ) or can even contribute to disease initiation (for example, in SCA 3, 40 ). Glutamate-mediated excitotoxicity is a prime example of neuron-glia toxicity that has been proposed to be a significant component in ALS 10, 23, 24 , SCA 3,40 and Huntington's disease (HD) 2 . PD, Parkinson's disease; MS, multiple sclerosis.
a Cd11b (now known as Itgam) promoterdriven Cre transgene), produced no delay of disease onset, survival was greatly extended through pronounced slowing of disease progression 8 . Similarly, replacing the entire myeloid lineage (including microglia) by transplantation of normal bone marrow cells into SOD1 mutant mice that could not make their own myeloid cells (owing to absence of the PU.1 transcription factor) had no effect on disease onset, but extended survival by slowing disease progression 7 . Similar transplantation to replace the entire myeloid lineage with mutant SOD1 cells, including all microglia, did not produce disease in an otherwise wildtype mouse (Fig. 2c) , conclusively demonstrating that the mutant expression within microglia and macrophages is not sufficient for motor neuron disease, but does drive rapid disease progression 7 .
Astrocytic glutamate transporters are of prime importance in protecting motor neurons against glutamate excitotoxicity. Altered glutamate handling is one of the few firm mechanistic links between sporadic and mutant SOD1-mediated ALS. In both mutant SOD1 animals 13, 14 and humans with ALS 23 , astrocytic GLT-1 glutamate transporters (and activity) are focally lost. This is likely to be of functional consequence for disease. Indeed, upregulating the GLT-1 transporter by transcriptional induction with b-lactam antibiotics, including ceftriaxone, extends survival in ALS mice 24 , and this approach is now the basis of an ongoing clinical trial.
Although the effect on disease course of reducing mutant SOD1 within astrocytes (for example, by selective gene excision) has not yet been reported, expressing mutant SOD1 at high levels within only astrocytes (using the Gfap-derived Gfa2 promoter) produces reactive astrocytosis, but is not sufficient to induce motor neuron degeneration 25 (Fig. 2d ). When coupled with the similar absence of neurodegeneration after high expression of mutant SOD1 within microglia 7 (see above; Fig. 2c ), it seems likely that mutant damage within both glial cell types rapidly accelerates disease progression 7, 8 . By contrast, mutant damage within the motor neurons is a key aspect driving disease initiation (Fig. 2a) . 10 . Enhanced synthesis of TNF-a by activated mutant microglia 28 was initially attractive, but now seems unlikely, as deletion of the gene encoding TNF-a does not affect mutant SOD1-mediated disease 29 . Neither is microglial (nor astrocytic, for that matter) production of nitric oxide a likely contributor, as deletion of iNOS, the inducible nitric oxide synthase, does not affect disease course 30 .
Mechanisms of glia-mediated neurotoxicity in ALS
Microglia are the source of NADPH oxidase, the main enzyme producing reactive oxygen species during inflammation. This multimeric oxidase is expressed by all phagocytes and is indispensable for protection against infectious microorganisms. It is also upregulated in familial and sporadic ALS and in mutant SOD1 mice 31 . Although this could simply reflect the strong microgliosis accompanying mutant SOD1-mediated disease, deletion from mice of the gene encoding the catalytic subunit (gp91 phox ) extends survival of mutant SOD1 mice 31 to exactly the same extent as does replacement of all mutant-expressing myeloid cells with normal ones 7 . It is thus likely that microglia-derived NADPH oxidase-dependent reactive oxygen species and the oxidative damage they cause are at least a part of the microglial component of non-cell-autonomous disease.
As for the contribution of astrocytes, cocultures of primary, mutant SOD1-expressing astrocytes 4,5 with primary motor neurons purified from embryos 5 , or with motor neurons generated in larger numbers by differentiation of mouse embryonic stem cells 4, 5 , have demonstrated that mutant astrocytes diminish motor neuron survival over a 2-week period (relative to similar cultures with normal glial cells). Astrocytederived toxicity (i) is selective for motor neurons, with no effect on sensory neurons or interneurons 5 , (ii) can be conferred by astrocyte conditioned media 5 and (iii) acts on wild-type as well as mutant-SOD1 motor neurons 4, 5 . The toxic species remains unidentified, however, and no signs of increased excitotoxicity could be detected in these in vitro systems 5 . Nevertheless, the reduced accumulation of GLT-1 that is almost universally seen in human ALS 10, 23 and animal models 13, 14 strongly supports an in vivo astrocyte-derived excitotoxic component to disease. Lastly, induction of chromogranin A synthesis in reactive astrocytes as well as neurons, combined with the proposal for an unusual, chromogranin-mediated secretion of mutant SOD1 (ref. 32) in ALS mice, implies that astrocytes and motor neurons may also drive disease progression through extracellular mutant SOD1. Consistent with an influence of extracellular mutant SOD1, both active and passive immunization to misfolded, mutant SOD1 can extend survival in ALS mice 33 . As extracellular mutant SOD1 is a potent activator of microglial cells 32 , this provides a non-cell-autonomous, feed-forward mechanism highlighting how reaction to actions from one cell type can accelerate toxicity to another once damage is initiated. SCA7 is caused by polyQ expansion in the gene encoding ataxin-7. An initial mouse model demonstrated that ataxia can be induced through a strictly cell-autonomous mechanism: selective expression of mutant ataxin-7 solely in Purkinje cells (using the Pcp2 promoter) produces a mild ataxia and neurodegeneration at advanced ages 36 . This was not that unexpected, as the polyQ-expanded mutant protein SCA1-linked ataxin-1 had already been shown to produce strong ataxia and prominent Purkinje cell degeneration when expressed from the same Purkinje cell-specific Pcp2 promoter 37 . More robust ataxin-7-mediated disease was achieved using a pan-neuronal (Pdgfb) promoter to direct synthesis of mutant ataxin-7 in Purkinje cells and all their interacting neurons 38 (Fig. 3a) . An even stronger ataxic phenotype with neurodegeneration was achieved by a knock-in strategy with mutant ataxin-7 that recapitulates endogenous ataxin-7 levels and expression pattern (widespread expression in neurons and glia), including expression within Purkinje cells 39 .
This was just the beginning of the story, however. Other mice were constructed in which mutant (polyQ-expanded) ataxin-7 was expressed from the Prnp promoter. In these mice, mutant ataxin-7 is expressed in many neurons and glia, but is conspicuously absent from Purkinje neurons 40 (Fig. 3b) . Nevertheless, the mice developed severe Purkinje degeneration and accompanying ataxia 40 . As damage to Bergmann glia identified in the Prnp-promoter mice was reminiscent of that found in humans with SCA7 and in the mutant ataxin-7 knockin mice 3, 39 , La Spada and colleagues tested whether mutant ataxin-7 expressed only in cerebellar Bergmann glia and other astrocytes (using the Gfap-derived Gfa2 promoter) would be sufficient for Purkinje toxicity 3 (Fig. 3c) . Ataxin-7 with expanded polyQ, but not wild-type ataxin-7, caused ataxia and degeneration of Purkinje neurons that did not express the mutant 3 , and it did so without generating other neurological deficits. Moreover, the Purkinje cell degeneration was remarkably similar to that induced by the much broader expression of ataxin-7 produced with the Prnp promoter 40 , demonstrating that toxicity could originate from Bergmann glia alone 3 .
Bergmann glia, which contain large amounts of the glutamate transporter GLAST, enwrap the glutamatergic synapses that granule cells and inferior olivary nuclei neurons make with Purkinje cell Figure 3 Non-cell-autonomous, glia-derived toxicity can lead to degeneration of Purkinje neurons in SCA7. (a-c) Although moderate Purkinje cell degeneration can be induced by expression (red) of mutant ataxin-7 in those neurons 36, 38 (a), in the normal setting mutant ataxin-7 is expressed in many other cells. Damage to these other cells does contribute to ataxia, as expression of mutant ataxin-7 in both surrounding neurons and glia but not in the Purkinje neurons themselves (using the promoter from the prion protein gene Prnp 40 ; b), or in the astrocytic Purkinje cell-associated Bergmann glia alone (using the Gfapderived Gfa2 promoter 3 ; c), is sufficient to provoke Purkinje cell degeneration. dendrites 35 . In the affected cerebellar regions of presymptomatic Gfa2 promoter-and Prnp promoter-driven mutant ataxin-7 mice, transporter-mediated uptake of glutamate at these Purkinje cell synapses was impaired 3 , as inferred from reduction in the GLAST glutamate transporter and its mRNA. Glutamate uptake was also reduced in mutant Bergmann glial cultures, cerebellar slices and cerebellar synaptosomes 3 .
The evidence in mice makes it clear that damage to Purkinje neurons can be mediated by mutant ataxin-7 synthesis solely within those neurons or solely within their neighboring support cells, the Bergmann glia. In the real disease setting, the mutant is expressed in both neuronal and glial partners (and many other cells too). Mechanistically, the simplest view is that the enormous size of the Purkinje cell dendritic tree and the correspondingly staggering numbers of glutamatergic synapses place Purkinje cells at risk upon even the smallest disturbances of glutamate uptake and consequent excitotoxicity. The disease mechanism, therefore, leading to ataxia and Purkinje cell degeneration in SCA7 mutants is non-cell-autonomous, with toxicity originating from damage both within Purkinje cells and within neighboring glial and neuronal cells as direct contributors to disease initiation and propagation.
Non-cell-autonomous neurotoxicity in Parkinson's disease Parkinson's disease is characterized by focal loss of dopaminergic neurons of the substantia nigra, producing the well known tremors and progressive stiffness. Although most disease is sporadic, several genetic causes are known, including dominant mutations in, or even increased synthesis of, a-synuclein, a highly abundant presynaptic protein (reviewed in ref. 41) . Intraneuronal accumulations of a-synuclein are found in several diseases, including sporadic Parkinson's disease and diffuse Lewy body disease (reviewed in ref. 41) , whereas in multiple system atrophy (MSA), whose clinical presentation includes Parkinsonism, ataxia and autonomic failure, a-synuclein-containing inclusions are actually more prominent in oligodendrocytes than in neurons; this is used as postmortem diagnostic confirmation of MSA (reviewed in ref. 42) . Although increased intraneuronal synthesis of a-synuclein was initially found to damage those neurons 43 , the potential for non-cell-autonomous damage from a-synuclein deposits came from demonstration that similar inclusions could form upon elevated expression selectively within the axonensheathing oligodendrocytes, thereby inducing secondary neurodegeneration of the associated neurons 6 .
Although direct tests similar to those used in ALS or SCA in mice to establish a non-cell-autonomous mechanism have not yet been reported in models of either Parkinson's disease or MSA, clear evidence for a non-cell-autonomous mechanism has come from chemically induced Parkinson's disease. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) can induce a Parkinsonian syndrome in humans and rodents almost indistinguishable from Parkinson's disease (reviewed in ref. 41 ). Toxicity to substantia nigral neurons requires conversion of MPTP into MPP + , a conversion that itself requires the (mostly) astrocytic enzyme monoamine oxidase B. Once released from astrocytes, MPP + is taken up by specific transporters that are expressed almost solely by the vulnerable neurons (reviewed in ref. 41) . Robust microgliosis (reviewed in ref. 42 ) that includes elevation of iNOS 9 indicates that there may be a microglial role in amplifying initial damage. This role of microglia is of mechanistic importance for disease, as iNOS null mice are more resistant to MPTP toxicity 9 . Further, both in vivo and in cell cocultures, the inflammatory modulator minocycline reduces MPTP neurotoxicity, and (at least in vitro) it does so only in the presence of microglia 44 . Thus, at least in this example of chemically induced Parkinson's disease, neurotoxicity requires the convergence of actions within astrocytes, microglia and the target neurons.
Non-cell-autonomous neurotoxicity in Huntington's disease Huntington's disease is a dominant, fatal, progressive disease characterized by prominent, age-dependent degeneration and death of striatal medium spiny neurons. Clinical presentation includes movement disorders (chorea and bradykinesia), psychiatric symptoms, and cognitive deficits, with a typical disease course of 15-20 years after a midlife onset. Huntington's disease is caused by polyQ expansion in the protein huntingtin, widely expressed in both neuronal and nonneuronal cells. The preferential loss of striatal neurons is by no means confined to this neuronal pool: other affected cells include cortical pyramidal neurons, and by end stage there is much wider cell loss in many other brain regions (reviewed in ref. 45) .
The Huntington's disease mechanism is non-cell-autonomous and based upon pathological cell-cell interactions, at least in rodents. This was demonstrated by selective transgene activation within specific neuronal cell types 46, 47 (achieved by Cre recombinase-mediated excision of a transcriptional stop cassette embedded in a single-copy transgene that, after excision, encodes exon 1 of huntingtin containing an expanded polyQ). Progressive motor deficits and striatocortical neuropathology were observed only when mutant huntingtin expression was activated (with nervous system-specific nestin (Nes) promoter-driven Cre expression) 46 in many neuronal (and glial) cell types, including striatal medium spiny neurons, cortical interneurons and cortical pyramidal neurons; deficits did not occur when its synthesis was restricted (using Emx1-Cre) 46 to cortical pyramidal neurons or (using Dlx5/6-Cre) 47 to striatal medium spiny neurons alone.
A direct test for a contribution from mutant huntingtin damage within glia cannot be easily implemented using this gene activation method; reports using the gene excision approach pioneered in mutant SOD1-mediated ALS are eagerly awaited. Nevertheless, substantial evidence makes microglial and astrocytic roles seem likely. Progressive reactive microgliosis is an established feature of disease in humans 48 and in several mouse models. The inflammatory modulator minocycline delays disease in mice generated by widespread expression of mutant huntingtin exon 1 (the R6/2 mouse model of Huntington's disease), and the delay is accompanied by decreased accumulation of microglial iNOS activity 49 . In the same mouse model, mutant huntingtin is expressed in many cell types, including astrocytes. Mutant huntingtin accumulates in astroglial nuclei of diseased brains, accompanied by decreased levels of the GLT-1 glutamate transporter and of transporter activity in Huntington's disease mouse models 2 . Perhaps most importantly, in mouse neuron-astrocyte cocultures, mutant astrocytes increase neuronal vulnerability to excitotoxicity 2 .
Conclusion
As most neurodegenerative disease-linked mutant proteins are widely expressed, it is likely that their expression outside the vulnerable neurons, especially within glial cells, contributes to disease mechanisms. Mutant products within glial cells drive toxicity to neighboring neurons either by release of toxic components or by mutant-mediated reduction in one or more neuronal support functions. In mutant SOD1-linked ALS, although mutant SOD1 expression in motor neurons is required for disease initiation, neurotoxicity is produced by damage within the neighboring mutant astrocytes, while damage within microglia drives rapid disease progression. Even more directly, in SCA7, degeneration of Purkinje cells can be induced by mutant ataxin-7 expression solely in the neighborhood of these cells, with astrocytic Bergmann glia a primary source of in vivo neurotoxicity.
Although the exact targets of glially mediated toxicity in these noncell-autonomous neurodegenerative disease mechanisms remain unproven, glutamate excitotoxicity mediated by reduced astrocytederived glutamate transport at synapses is the most promising candidate. Damage from mutant astrocytes and microglia could also impair dendritic signaling (in turn inducing synaptic pruning) or impair the required contributions of axon-ensheathing myelinating glial cells to axonal maintenance (with a consequent disturbance in axonal transport).
Disease mechanisms in many (if not all) of the principal neurodegenerative diseases are all but certain to be non-cell-autonomous and to crucially involve glia. A central contribution of glia to disease pathogenesis has raised the likelihood that onset of disease and progression of disease may be driven by damage from mutant proteins acting within cell types different from one another, a point now established for inherited ALS. This realization is important for the design of disease therapies, especially when considering development of stem cell-based approaches. Instead of the extremely challenging task of functionally replacing the lost neurons, a supply of normal (or therapeutically modified) glial cells (at least some of which will probably migrate to sites of initial damage) may represent a more feasible alternative for diluting the toxic action of mutant glia around the remaining neurons, as well as bolstering the supporting role(s) provided by undamaged, normal glia.
